Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 197 articles:
HTML format



Single Articles


    November 2022
  1. CHEN WY, Lu SH, Wang YM, Wang CW, et al
    Post-irradiation Sarcoma after Definitive Radiation Therapy for Nasopharyngeal Carcinoma.
    Radiother Oncol. 2022 Nov 23:S0167-8140(22)04560.
    PubMed     Abstract available


  2. LIU ZC, Zeng KH, Gu ZB, Chen RP, et al
    Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching.
    Radiother Oncol. 2022 Nov 18:S0167-8140(22)04554.
    PubMed     Abstract available


  3. WANG G, Huang C, Yang K, Guo R, et al
    Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04548.
    PubMed     Abstract available


  4. YAO JJ, Jin YN, Lin YJ, Zhang WJ, et al
    The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04547.
    PubMed     Abstract available


  5. BIN Y, Meng Z, Huang LL, Hu XY, et al
    Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04549.
    PubMed     Abstract available


  6. TAKADA A, Ichikawa Y, Nakamura S, Toyomasu Y, et al
    Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging.
    Radiother Oncol. 2022 Nov 10. pii: S0167-8140(22)04546.
    PubMed    


  7. ZHONG Z, Wang D, Liu Y, Shao S, et al
    Lymph Drainage and Cervical Fascia Anatomy-Oriented Differential Nodal CTV Delineation at the Supraclavicular Region for Esophageal Cancer and Nasopharyngeal Cancer.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04531.
    PubMed    


  8. CHOW JCH, Lui JCF, Cheung KM, Tam AHP, et al
    Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04529.
    PubMed     Abstract available


  9. HUANG H, Miao J, Zhao C, Wang L, et al
    Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing inten
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04517.
    PubMed    


  10. SARODE GS, Sarode SC, Anand R
    Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective pha
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04515.
    PubMed    


  11. LEE CT, Litwin S, Yao CMKL, Liu JC, et al
    Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints.
    Radiother Oncol. 2022;176:215-221.
    PubMed     Abstract available


    October 2022
  12. ROESCH J, Oertel M, Wegen S, Trommer M, et al
    Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
    Radiother Oncol. 2022 Oct 20. pii: S0167-8140(22)04502.
    PubMed     Abstract available


  13. TIEN CT, Chen CN, Young YH
    Post-irradiation endolymphatic hydrops vs. post-irradiation sudden deafness.
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04504.
    PubMed     Abstract available


  14. RONN HANSEN C, Price G, Field M, Sarup N, et al
    Larynx cancer survival model developed through open-source federated learning.
    Radiother Oncol. 2022 Oct 5. pii: S0167-8140(22)04493.
    PubMed     Abstract available


    September 2022
  15. NADERI E, Schack LMH, Welsh C, Sim AYL, et al
    Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer.
    Radiother Oncol. 2022 Sep 30. pii: S0167-8140(22)04486.
    PubMed     Abstract available


  16. HUMBERT-VIDAN L, Hansen CR, Fuller CD, Petit S, et al
    Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for Mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).
    Radiother Oncol. 2022 Sep 27. pii: S0167-8140(22)04473.
    PubMed    


  17. DRAGUET C, Barragan-Montero AM, Chocan Vera M, Thomas M, et al
    Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancer.
    Radiother Oncol. 2022 Sep 24. pii: S0167-8140(22)04263.
    PubMed     Abstract available


  18. OUD M, Breedveld S, Gizynska M, Kroesen M, et al
    An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer.
    Radiother Oncol. 2022 Sep 20. pii: S0167-8140(22)04278.
    PubMed     Abstract available


  19. TOPKAN E, Somay E, Yilmaz B
    In regard to recent published study of Massaccesi et al. titled 'A predictive nomogram for trismus after radiotherapy for head and neck cancer'. (Radiother Oncol. 2022 Jun 2: S0167-8140(22)04137-8. doi: 10.1016/j.radonc.2022.05.031).
    Radiother Oncol. 2022;174:132.
    PubMed    


  20. KOO J, Caudell JJ, Latifi K, Jordan P, et al
    Comparative evaluation of a prototype deep learning algorithm for autosegmentation of normal tissues in head and neck radiotherapy.
    Radiother Oncol. 2022;174:52-58.
    PubMed     Abstract available


    August 2022
  21. DE ROEST RH, van der Heijden M, W R Wesseling F, de Ruiter EJ, et al
    Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    Radiother Oncol. 2022 Aug 13. pii: S0167-8140(22)04234.
    PubMed     Abstract available


  22. ZHANG Y, Alshaikhi J, Amos RA, Lowe M, et al
    Improving workflow for adaptive proton therapy with predictive anatomical modelling: A proof of concept.
    Radiother Oncol. 2022;173:93-101.
    PubMed     Abstract available


    July 2022
  23. GHATASHEH H, Hui Huang S, Su J, Xu W, et al
    Evaluation of risk-tailored individualized selection of radiation therapy target volume for Head and Neck Carcinoma of Unknown Primary.
    Radiother Oncol. 2022 Jul 26. pii: S0167-8140(22)04214.
    PubMed     Abstract available


  24. HABRICH J, Boeke S, Nachbar M, Nikolaou K, et al
    Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac.
    Radiother Oncol. 2022 Jul 25. pii: S0167-8140(22)04218.
    PubMed     Abstract available


  25. HUANG H, Miao J, Xiao X, Hu J, et al
    Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): a prospective phase II randomized controlled study.
    Radiother Oncol. 2022 Jul 8. pii: S0167-8140(22)04191.
    PubMed     Abstract available


  26. PRICE JM, West CM, Dixon LM, Iyizoba-Ebozue Z, et al
    Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study.
    Radiother Oncol. 2022;172:111-117.
    PubMed     Abstract available


  27. WANG J, Liu Y, Shayan G, Ma Y, et al
    Lymph node ratio-dependent prognosis stratification and postoperative radiotherapy utilization in T1-2N1 oral cavity carcinoma.
    Radiother Oncol. 2022;172:83-90.
    PubMed     Abstract available


  28. NIU X, Liu P, Zhou X, Wang X, et al
    Is postoperative radiotherapy an essential treatment for nonmetastatic lymphoepithelial carcinoma of the salivary gland?
    Radiother Oncol. 2022;172:76-82.
    PubMed     Abstract available


  29. FRIED DV, Zhu T, Das SK, Shen C, et al
    Prospective assessment of sparing the parotid ducts via MRI sialography for reducing patient reported xerostomia.
    Radiother Oncol. 2022;172:42-49.
    PubMed     Abstract available


  30. HOFFMANN L, Mortensen H, Shamshad M, Berbee M, et al
    Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres.
    Radiother Oncol. 2022;172:32-41.
    PubMed     Abstract available


    June 2022
  31. QIAN D, Chen X, Shang X, Wang Y, et al
    Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II rando
    Radiother Oncol. 2022 Jun 25. pii: S0167-8140(22)04176.
    PubMed     Abstract available


  32. KROESE TE, Christ SM, van Rossum PSN, Burger MDL, et al
    Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.
    Radiother Oncol. 2022 Jun 23. pii: S0167-8140(22)04173.
    PubMed     Abstract available


  33. GONG J, Zhang W, Huang W, Liao Y, et al
    CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: a multicenter study.
    Radiother Oncol. 2022 Jun 21. pii: S0167-8140(22)04171.
    PubMed     Abstract available


  34. HANSEN CR, Price G, Field M, Sarup N, et al
    Open-source distributed learning validation for a larynx cancer survival model following radiotherapy.
    Radiother Oncol. 2022 Jun 20. pii: S0167-8140(22)04170.
    PubMed     Abstract available


  35. FU G, Xie Y, Pan J, Qiu Y, et al
    Longitudinal study of irradiation-induced brain functional network alterations in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Jun 16. pii: S0167-8140(22)04164.
    PubMed     Abstract available


  36. SCHOONBEEK RC, Festen S, van der Laan BFAM, Plaat BEC, et al
    The effect of delayed treatment initiation on adverse events and recurrence in older head and neck cancer patients.
    Radiother Oncol. 2022 Jun 6. pii: S0167-8140(22)04146.
    PubMed     Abstract available


  37. MASSACCESI M, Dinapoli N, Fuga V, Rupe C, et al
    A predictive nomogram for trismus after radiotherapy for head and neck cancer.
    Radiother Oncol. 2022 Jun 2. pii: S0167-8140(22)04137.
    PubMed     Abstract available


  38. PATIL S, Linge A, Grosser M, Lohaus F, et al
    Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
    Radiother Oncol. 2022;171:91-100.
    PubMed     Abstract available


    May 2022
  39. ZHAO DW, Fan WJ, Fang XM, Luo YR, et al
    Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Radiother Oncol. 2022 May 15. pii: S0167-8140(22)00251.
    PubMed     Abstract available


  40. YI-LIANG SHEN E, Hung TM, Tsan DL, Cheng NM, et al
    Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 May 11. pii: S0167-8140(22)00240.
    PubMed     Abstract available


  41. BIAU J, Nutting C, Langendijk JA, Frederic-Moreau T, et al
    Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers.
    Radiother Oncol. 2022;170:48-54.
    PubMed     Abstract available


  42. SOOKAROMDEE P, Wiwanitkit V
    Comment on "Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC".
    Radiother Oncol. 2022;170:250.
    PubMed    


  43. LOCK S, Baumann M
    Response to comment on "Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC".
    Radiother Oncol. 2022;170:251.
    PubMed    


  44. PERGOLIZZI S, Ferini G, Parisi S
    Letter to the editor of radiotherapy and oncology regarding of the paper "Stereotactic body radiotherapy for head and neck skin cancer" by IS Voruganti et al.
    Radiother Oncol. 2022;170:247.
    PubMed    


  45. KARAM I, Voruganti IS, Poon I
    Response letter to the Editor of Radiotherapy and Oncology regarding the paper "Stereotactic body radiotherapy for head and neck skin cancer" by IS Voruganti et al.
    Radiother Oncol. 2022;170:248-249.
    PubMed    


    April 2022
  46. ZHAO Y, Liao X, Wang Y, Lan W, et al
    Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy.
    Radiother Oncol. 2022 Apr 29. pii: S0167-8140(22)00232.
    PubMed     Abstract available


  47. DOHOPOLSKI M, Wang K, Morgan H, Sher D, et al
    Predicting the need for aggressive nutritional supplementation in head and neck cancer patients receiving radiation therapy.
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00224.
    PubMed     Abstract available


  48. SHEN H, Yin J, Niu R, Lian Y, et al
    Development and validation of a radiomic nomogram to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carc
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00222.
    PubMed     Abstract available


  49. LEE BM, Lee CG
    Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.
    Radiother Oncol. 2022 Apr 18. pii: S0167-8140(22)00191.
    PubMed     Abstract available


  50. WELZ S, Paulsen F, Pfannenberg C, Reimold M, et al
    Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [(18)F]FMISO PET/CT.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00170.
    PubMed     Abstract available


  51. JENSEN KH, Vogelius IR, Bernsdorf M, Gothelf A, et al
    Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00169.
    PubMed     Abstract available


  52. MULLER J, Leger S, Zwanenburg A, Suckert T, et al
    Radiomics-based tumor phenotype determination based on medical imaging and tumor microenvironment in a preclinical setting.
    Radiother Oncol. 2022;169:96-104.
    PubMed     Abstract available


  53. LOCK S, Linge A, Lohaus F, Ebert N, et al
    Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
    Radiother Oncol. 2022;169:8-14.
    PubMed     Abstract available


  54. ZHU J, Tan Y, Wang Q
    Letter to the editor regarding the article "Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis" by Chow et al.
    Radiother Oncol. 2022;169:152-153.
    PubMed    


  55. LUDWIG R, Hoffmann JM, Pouymayou B, Dappen MB, et al
    Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface.
    Radiother Oncol. 2022;169:1-7.
    PubMed     Abstract available


  56. KAO YS, Chen YF
    Comment to "Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis".
    Radiother Oncol. 2022;169:163.
    PubMed    


    March 2022
  57. YUE M, Xue X, Wang Z, Lambo RL, et al
    Dose prediction via distance-guided deep learning: initial development for nasopharyngeal carcinoma radiotherapy.
    Radiother Oncol. 2022 Mar 26. pii: S0167-8140(22)00150.
    PubMed     Abstract available


  58. BORDERIAS-VILLARROEL E, Taasti V, Van Elmpt W, Teruel-Rivas S, et al
    Evaluation of the clinical value of automatic online dose restoration for adaptive proton therapy of head and neck cancer.
    Radiother Oncol. 2022 Mar 25. pii: S0167-8140(22)00149.
    PubMed     Abstract available


  59. KARAVOLIA E, van Rijn-Dekker MI, Van den Bosch L, van den Hoek JGM, et al
    Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
    Radiother Oncol. 2022 Mar 15. pii: S0167-8140(22)00145.
    PubMed     Abstract available


  60. ZHOU X, Wang W, Zhou C, Zhu J, et al
    Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: An updated and expanded retrospective analysis.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00132.
    PubMed     Abstract available


  61. HUANG CC, Lai YR, Chiu WC, Fang FM, et al
    Concurrent chemoradiation therapy is associated with an accelerated risk of cardiovascular autonomic dysfunction in patients with nasopharyngeal carcinoma: A 9-year prospective follow-up study.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00129.
    PubMed     Abstract available


  62. CHOW R, Simone CB 2nd
    Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality.
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00112.
    PubMed    


  63. DAI D, Tian Q, Shui Y, Li J, et al
    Response to "Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality".
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00109.
    PubMed    


  64. NACHANKAR A, Musha A, Kubo N, Kawamura H, et al
    Dosimetric analysis of intraocular hemorrhage in nonsquamous head and neck cancers treated with carbon-ion radiotherapy.
    Radiother Oncol. 2022 Mar 4. pii: S0167-8140(22)00118.
    PubMed     Abstract available


  65. NORTH VS, Tran AQ, Kazim M
    Orbital adenoid cystic carcinoma arising from nasopharyngeal salivary gland origin.
    Radiother Oncol. 2022;168:104-105.
    PubMed    


  66. GORPHE P, Classe M, Ammari S, Garcia G, et al
    Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma.
    Radiother Oncol. 2022;168:40-45.
    PubMed     Abstract available


    February 2022
  67. BONOMO P, Desideri I, Mangoni M, Saieva C, et al
    Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial.
    Radiother Oncol. 2022 Feb 11. pii: S0167-8140(22)00091.
    PubMed     Abstract available


  68. SCANDURRA D, Meijer TWH, Free J, van den Hoek JGM, et al
    Evaluation of robustly optimised intensity modulated proton therapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Feb 5. pii: S0167-8140(22)00080.
    PubMed     Abstract available


  69. PAN D, Rong X, Zhu Y, Ng WT, et al
    A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis.
    Radiother Oncol. 2022 Feb 1. pii: S0167-8140(22)00060.
    PubMed     Abstract available


  70. PATIL S, Tawk B, Grosser M, Lohaus F, et al
    Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
    Radiother Oncol. 2022;167:300-307.
    PubMed     Abstract available


  71. TAMBAS M, van der Laan HP, Steenbakkers RJHM, Doyen J, et al
    Current practice in proton therapy delivery in adult cancer patients across Europe.
    Radiother Oncol. 2022;167:7-13.
    PubMed     Abstract available


  72. CHANG CW, Wang C, Lu CJ, Wang CW, et al
    Incidence and prognostic significance of extranodal extension in isolated nodal recurrence of oral squamous cell carcinoma.
    Radiother Oncol. 2022;167:81-88.
    PubMed     Abstract available


    January 2022
  73. SUN XS, Zhu MY, Wen DX, Luo DH, et al
    Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in local recurrence nasopharyngeal carcinoma patients.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00028.
    PubMed     Abstract available


  74. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Head and neck cancer diagnoses and faster treatment initiation during COVID-19: correspondence.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00026.
    PubMed    


  75. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence".
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00033.
    PubMed    


  76. CHATTERJEE S, Maulik S, Prasath S, Arun B, et al
    Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: Results of a prospective cohort study (Study ID CTRI/2017/11/010683).
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00024.
    PubMed     Abstract available


  77. ZECH HB, Berger J, Mansour WY, Nordquist L, et al
    Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00022.
    PubMed     Abstract available


  78. AL-MAMGANI A, Kessels R, Janssen T, Navran A, et al
    The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction.
    Radiother Oncol. 2022 Jan 20. pii: S0167-8140(22)00017.
    PubMed     Abstract available


  79. HE J, Qian L, Gao J
    Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00005.
    PubMed    


  80. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)"by He et al.
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00006.
    PubMed    


  81. DAI D, Tian Q, Shui Y, Li J, et al
    The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2022 Jan 8. pii: S0167-8140(22)00007.
    PubMed     Abstract available


  82. HUANG W, Zhang Q, Wu G, Chen P, et al
    Corrigendum to "DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients" [Radiother Oncol (2021) 164:146-154].
    Radiother Oncol. 2022 Jan 7. pii: S0167-8140(21)09059.
    PubMed    


  83. LIU T, Shen BW, Liu LT, Yang ZC, et al
    Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model.
    Radiother Oncol. 2022 Jan 5. pii: S0167-8140(21)09094.
    PubMed     Abstract available


  84. HONG CR, Buckley CD, Wong WW, Anekal PV, et al
    Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
    Radiother Oncol. 2022;166:162-170.
    PubMed     Abstract available


  85. FORNER LE, Dieleman FJ, Shaw RJ, Kanatas A, et al
    Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
    Radiother Oncol. 2022;166:137-144.
    PubMed     Abstract available


  86. WENNERBERG J, Gebre-Medhin M, Nilsson P, Brun E, et al
    Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity - The ARTSCAN 2 study.
    Radiother Oncol. 2022;166:26-32.
    PubMed     Abstract available


    December 2021
  87. GUO Q, Xiao N, Xu H, Zong J, et al
    Rationality of the international guideline's recommendation regarding selective coverage of level Ib in clinical target volume with nasopharyngeal carcinoma: Results from a real-world series.
    Radiother Oncol. 2021 Dec 29. pii: S0167-8140(21)09081.
    PubMed     Abstract available


  88. TANG SQ, Chen L, Li WF, Chan ATC, et al
    Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
    Radiother Oncol. 2021 Dec 28. pii: S0167-8140(21)09077.
    PubMed     Abstract available


  89. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis.
    Radiother Oncol. 2021 Dec 13. pii: S0167-8140(21)09049.
    PubMed     Abstract available


  90. MUSHA A, Hirai C, Kitada Y, Tsunoda A, et al
    Relationship between oral mucositis and the oral bacterial count in patients with head and neck cancer undergoing carbon ion radiotherapy: A prospective study.
    Radiother Oncol. 2021 Dec 10. pii: S0167-8140(21)09054.
    PubMed     Abstract available


  91. BEUKEMA JC, de Groot C, Plukker JTM, Vliegenthart R, et al
    Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study.
    Radiother Oncol. 2021 Dec 2. pii: S0167-8140(21)09025.
    PubMed     Abstract available


  92. CHOW R, Murdy K, Vaska M, Lee SL, et al
    Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis.
    Radiother Oncol. 2021;165:37-43.
    PubMed     Abstract available


  93. VORUGANTI IS, Poon I, Husain ZA, Bayley A, et al
    Stereotactic body radiotherapy for head and neck skin cancer.
    Radiother Oncol. 2021;165:1-7.
    PubMed     Abstract available


    November 2021
  94. KUTZ LM, Abel J, Schweizer D, Tribius S, et al
    Quality of life, HPV-status and phase angle predict survival in head and neck cancer patients under (chemo)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09004.
    PubMed     Abstract available


  95. JIN YN, Yang QQ, Li ZQ, Ou XQ, et al
    Development of a Web-based Prognostic Model to Quantify the Survival Benefit of Cumulative Cisplatin Dose during Concurrent Chemoradiotherapy in Childhood Nasopharyngeal Carcinoma.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09008.
    PubMed     Abstract available


  96. NISHIBUCHI I, Murakami Y, Kubo K, Imano N, et al
    Temporal Changes and Risk Factors for Esophageal Stenosis after Salvage Radiotherapy in Superficial Esophageal Cancer following Non-Curative Endoscopic Submucosal Dissection.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09007.
    PubMed     Abstract available


  97. PATEL V, Kwok J, Burke M, Urbano TG, et al
    Should the HPV positive oropharyngeal cancer patient be considered for a two-stage dental assessment for their radiation treatment?
    Radiother Oncol. 2021;164:232-235.
    PubMed     Abstract available


  98. GAN Y, Langendijk JA, Oldehinkel E, Scandurra D, et al
    A novel semi auto-segmentation method for accurate dose and NTCP evaluation in adaptive head and neck radiotherapy.
    Radiother Oncol. 2021;164:167-174.
    PubMed     Abstract available


  99. RUI M, Zhang X, Huang J, Wei D, et al
    The baseline oral microbiota predicts the response of locally advanced oral squamous cell carcinoma patients to induction chemotherapy: A prospective longitudinal study.
    Radiother Oncol. 2021;164:83-91.
    PubMed     Abstract available


    October 2021
  100. BROOKER RC, Antczak P, Liloglou T, Risk JM, et al
    Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy.
    Radiother Oncol. 2021;165:87-93.
    PubMed     Abstract available


  101. CHIN O, Yu E, O'Sullivan B, Su J, et al
    Prognostic Importance of Radiologic Extranodal Extension in Nasopharyngeal Carcinoma Treated in a Canadian Cohort.
    Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08785.
    PubMed     Abstract available


  102. ZHANG ZM, Zhao R, Bao Y, Zhou LX, et al
    A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08758.
    PubMed     Abstract available


  103. SHI Z, Zhu X, Ke S, Qiu H, et al
    Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08754.
    PubMed     Abstract available


  104. YAN A, Hanna A, Wilson TG, Deraniyagala R, et al
    Correlation between tumor voxel dose response matrix and tumor biomarker profile in patients with head and neck squamous cell carcinoma.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)08748.
    PubMed     Abstract available


  105. KANEHIRA T, van Kranen S, Jansen T, Hamming-Vrieze O, et al
    Comparisons of normal tissue complication probability models derived from planned and delivered dose for head and neck cancer patients.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)06738.
    PubMed     Abstract available


    September 2021
  106. HUANG W, Zhang Q, Wu G, Pian Chen P, et al
    DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2021 Sep 27. pii: S0167-8140(21)06739.
    PubMed     Abstract available


  107. WAGENAAR D, Schuit E, van der Schaaf A, Langendijk JA, et al
    Can the mean linear energy transfer of organs be directly related to patient toxicities for current head and neck cancer intensity-modulated proton therapy practice?
    Radiother Oncol. 2021 Sep 14. pii: S0167-8140(21)06723.
    PubMed     Abstract available


  108. WANG X, Hobbs B, Gandhi SJ, Muijs CT, et al
    Current Status and Application of Proton Therapy for Esophageal Cancer.
    Radiother Oncol. 2021 Sep 14. pii: S0167-8140(21)06724.
    PubMed     Abstract available


  109. CHOW JCH, Lee A, Bao KKH, Cheung KM, et al
    Cranial neuropathies in advanced nasopharyngeal carcinoma: Neurological recovery after modern radiotherapy and systemic chemotherapy.
    Radiother Oncol. 2021 Sep 7. pii: S0167-8140(21)06716.
    PubMed     Abstract available


    August 2021
  110. KROESE TE, Jairam J, Ruurda JP, Lin SH, et al
    Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: incidence and external validation of a prediction model.
    Radiother Oncol. 2021 Aug 25. pii: S0167-8140(21)06703.
    PubMed     Abstract available


  111. LIU T, Liu LT, Lin JY, Shen BW, et al
    Management of Suboptimal Response to Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Re-induction Therapy or Direct to Radiotherapy?
    Radiother Oncol. 2021 Aug 25. pii: S0167-8140(21)06704.
    PubMed     Abstract available


  112. MUSHA A, Shimada H, Kubo N, Kawamura H, et al
    Clinical features and dosimetric evaluation of carbon ion radiation-induced osteoradionecrosis of mandible in head and neck tumors.
    Radiother Oncol. 2021;161:205-210.
    PubMed     Abstract available


  113. WENTZEL A, Luciani T, van Dijk LV, Taku N, et al
    Precision association of lymphatic disease spread with radiation-associated toxicity in oropharyngeal squamous carcinomas.
    Radiother Oncol. 2021;161:152-158.
    PubMed     Abstract available


  114. N B P, Ravi KS, Durgapal P
    Discovery of new salivary gland - A substantial histological analysis.
    Radiother Oncol. 2021;161:92-94.
    PubMed     Abstract available


  115. GREGOIRE V, Bauwens L
    Reply to sanguineti regarding the manuscript untitled "Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma".
    Radiother Oncol. 2021;161:253.
    PubMed    


  116. SANGUINETI G
    Re: Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. Radiother Oncol, 2021. 157: p. 122-129.
    Radiother Oncol. 2021;161:251-252.
    PubMed    


  117. SHARABIANI M, Clementel E, Andratschke N, Collette L, et al
    Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis.
    Radiother Oncol. 2021;161:35-39.
    PubMed     Abstract available


    July 2021
  118. WANG XY, Zhu SY, Wu WJ, Li HJ, et al
    Corrigendum to "Extent of paranasal sinus involvement and its prognostic value in nasopharyngeal carcinoma: Proposed modification in the current UICC/AJCC staging system" [Radiother Oncol 160 (2021) 221-227].
    Radiother Oncol. 2021 Jul 31. pii: S0167-8140(21)06644.
    PubMed    


  119. YANG G, Feng D, Li F, Luo B, et al
    A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma.
    Radiother Oncol. 2021 Jul 31. pii: S0167-8140(21)06667.
    PubMed     Abstract available


  120. PARSAI S, Lei J Qiu R, Qi P, Sedor G, et al
    In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation.
    Radiother Oncol. 2021 Jul 29. pii: S0167-8140(21)06666.
    PubMed     Abstract available


  121. AL-MAMGANI A, Kessels R, Navran A, Hamming-Vrieze O, et al
    Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes.
    Radiother Oncol. 2021 Jul 23. pii: S0167-8140(21)06659.
    PubMed     Abstract available


  122. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on "Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)" by Baiocchi et al.
    Radiother Oncol. 2021 Jul 15. pii: S0167-8140(21)06639.
    PubMed    


  123. MUNARETTO TIMM BAIOCCHI J, Fischer-Sgrott F, Baiocchi Neto G
    Comment on "Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2021 Jul 15. pii: S0167-8140(21)06642.
    PubMed    


  124. JO YY, Yu J, Song KJ, Jang JY, et al
    Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: a retrospective study.
    Radiother Oncol. 2021 Jul 12. pii: S0167-8140(21)06643.
    PubMed     Abstract available


  125. BOEKHOFF MR, Defize IL, Borggreve AS, van Hillegersberg R, et al
    An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients.
    Radiother Oncol. 2021 Jul 5. pii: S0167-8140(21)06626.
    PubMed     Abstract available


  126. VAN DER LAAN HP, van der Schaaf A, Van den Bosch L, Korevaar EW, et al
    Quality of life and toxicity guided treatment plan optimisation for head and neck cancer.
    Radiother Oncol. 2021 Jul 5. pii: S0167-8140(21)06623.
    PubMed     Abstract available


  127. CARSUZAA F, Lapeyre M, Gregoire V, Maingon P, et al
    Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus.
    Radiother Oncol. 2021;160:140-147.
    PubMed     Abstract available


  128. CHEN X, Sun S, Bai N, Han K, et al
    A deep learning-based auto-segmentation system for organs-at-risk on whole-body computed tomography images for radiation therapy.
    Radiother Oncol. 2021;160:175-184.
    PubMed     Abstract available


  129. SAMBASIVAN K, Sassoon I, Thavaraj S, Kennedy R, et al
    TNM 8 staging is a better prognosticator than TNM 7 for patients with locally advanced oral cavity squamous cell carcinoma treated with surgery and post-operative radiotherapy.
    Radiother Oncol. 2021;160:54-60.
    PubMed     Abstract available


  130. CAO J, Zhang X, Jiang B, Chen J, et al
    Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia.
    Radiother Oncol. 2021;160:32-39.
    PubMed     Abstract available


    June 2021
  131. SUN XS, Xie SY, Luo DH, Liu LT, et al
    Impact of smoking on survival in nasopharyngeal carcinoma: A cohort study with 23,325 patients diagnosed from 1990 to 2016.
    Radiother Oncol. 2021 Jun 25. pii: S0167-8140(21)06612.
    PubMed     Abstract available


  132. DONNELLY O, Goranova R, Nugent M
    Letter to the editor regarding the article "Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)" by Robijns et al. Radiat Oncol. 2021.
    Radiother Oncol. 2021 Jun 15. pii: S0167-8140(21)06579.
    PubMed    


  133. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Letter to the editor by Donnelly et al. regarding the article "Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2021 Jun 10. pii: S0167-8140(21)06581.
    PubMed    


  134. JIN YN, Yao JJ, You YF, Cao HJ, et al
    Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study.
    Radiother Oncol. 2021 Jun 8. pii: S0167-8140(21)06575.
    PubMed     Abstract available


  135. DE BREE R, Swartz JE, Bril S, Chargi N, et al
    Skeletal muscle mass measurements using head and neck CT imaging in head and neck cancer patients.
    Radiother Oncol. 2021 Jun 6. pii: S0167-8140(21)06573.
    PubMed    


  136. LALONDE A, Bobic M, Winey B, Verburg J, et al
    Anatomic changes in head and neck intensity-modulated proton therapy: Comparison between robust optimization and online adaptation.
    Radiother Oncol. 2021;159:39-47.
    PubMed     Abstract available


    May 2021
  137. JIANG C, Gong B, Gao H, Zhang T, et al
    Correlation analysis of neck node levels in 960 cases of Nasopharyngeal carcinoma (NPC).
    Radiother Oncol. 2021 May 24. pii: S0167-8140(21)06258.
    PubMed     Abstract available


  138. BOEKHOFF MR, Defize IL, Borggreve AS, van Hillegersberg R, et al
    CTV-to-PTV margin assessment for esophageal cancer radiotherapy based on an accumulated dose analysis.
    Radiother Oncol. 2021 May 13. pii: S0167-8140(21)06241.
    PubMed     Abstract available


  139. WANG XY, Zhu SY, Wu WJ, Li HJ, et al
    Extent of Paranasal Sinus Involvement and its Prognostic Value in Nasopharyngeal Carcinoma: Proposed Modification in the Current UICC/AJCC staging system.
    Radiother Oncol. 2021 May 10. pii: S0167-8140(21)06224.
    PubMed     Abstract available


  140. SUN Z, Hu S, Xue Q, Jin L, et al
    Can 3D pseudo-continuous arterial spin labeling perfusion imaging be applied to predict early response to chemoradiotherapy in patients with advanced nasopharyngeal carcinoma?
    Radiother Oncol. 2021 May 2. pii: S0167-8140(21)06214.
    PubMed     Abstract available


  141. CIECIOR W, Ebert N, Borgeaud N, Thames HD, et al
    Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models.
    Radiother Oncol. 2021;158:262-267.
    PubMed     Abstract available


  142. LAI Y, Zeng X, Zhou K, Zhou X, et al
    End to end intussusception anastomosis decreases the risk of anastomotic leakage after neoadjvant chemoradiation and McKeown oesophagectomy.
    Radiother Oncol. 2021;158:285-292.
    PubMed     Abstract available


  143. HAGUE C, McPartlin A, Lee LW, Hughes C, et al
    An evaluation of MR based deep learning auto-contouring for planning head and neck radiotherapy.
    Radiother Oncol. 2021;158:112-117.
    PubMed     Abstract available


  144. LEE J, Liu SH, Chen JC, Leu YS, et al
    Progressive muscle loss is an independent predictor for survival in locally advanced oral cavity cancer: A longitudinal study.
    Radiother Oncol. 2021;158:83-89.
    PubMed     Abstract available


  145. ZHAO L, Chen S, Chen S, Pang Y, et al
    (68)Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer.
    Radiother Oncol. 2021;158:55-61.
    PubMed     Abstract available


    April 2021
  146. TAMBAS M, der Laan HPV, Rutgers W, van den Hoek JGM, et al
    Development of advanced preselection tools to reduce redundant plan comparisons in model-based selection of head and neck cancer patients for proton therapy.
    Radiother Oncol. 2021 Apr 20. pii: S0167-8140(21)06194.
    PubMed     Abstract available


  147. VAN DER LAAN HP, Van den Bosch L, Schuit E, Steenbakkers RJHM, et al
    aImpact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer.
    Radiother Oncol. 2021 Apr 20. pii: S0167-8140(21)06193.
    PubMed     Abstract available


  148. ELICIN O, Koller Brolese E, Bojaxhiu B, Sermaxhaj B, et al
    The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer.
    Radiother Oncol. 2021 Apr 10. pii: S0167-8140(21)06185.
    PubMed     Abstract available


  149. ESTEBAN B, Pierre P, Camille S, Pascal P, et al
    Influence of postoperative radiotherapy target volumes in unilateral head and neck carcinoma of unknown primary: a multicentric study using propensity score.
    Radiother Oncol. 2021 Apr 9. pii: S0167-8140(21)06183.
    PubMed     Abstract available


  150. LU ZJ, Liu LT, Sun XS, Guo SS, et al
    Establishment and validation of a prognostic nomogram to predict early metastasis in nasopharyngeal carcinoma patients within six months after radiotherapy and to guide intensive treatment.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06175.
    PubMed     Abstract available


  151. YAN JJ, Guo SS, Lin DF, Liu LT, et al
    Development and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06180.
    PubMed     Abstract available


  152. QIU Y, Guo Z, Lin X, Li J, et al
    Standard radiotherapy for patients with nasopharyngeal carcinoma results in progressive tract-specific brain white matter alterations: A one-year follow-up via diffusion tensor imaging.
    Radiother Oncol. 2021 Apr 8. pii: S0167-8140(21)06179.
    PubMed     Abstract available


  153. ZHANG Y, Feng W, Gao LT, Cai XW, et al
    Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma.
    Radiother Oncol. 2021 Apr 1. pii: S0167-8140(21)06171.
    PubMed     Abstract available


  154. WONG ET, Huang SH, O'Sullivan B, Persaud V, et al
    Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy.
    Radiother Oncol. 2021;157:255-262.
    PubMed     Abstract available


  155. JENSEN GL, Axelrud G, Fink D, Hammonds K, et al
    Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT.
    Radiother Oncol. 2021;157:234-240.
    PubMed     Abstract available


  156. BAUWENS L, Baltres A, Fiani DJ, Zrounba P, et al
    Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2021;157:122-129.
    PubMed     Abstract available


  157. GUNN L, Gilbert J, Nenclares P, Soliman H, et al
    Taste dysfunction following radiotherapy to the head and neck: A systematic review.
    Radiother Oncol. 2021;157:130-140.
    PubMed     Abstract available


  158. MEN K, Chen X, Yang B, Zhu J, et al
    Automatic segmentation of three clinical target volumes in radiotherapy using lifelong learning.
    Radiother Oncol. 2021;157:1-7.
    PubMed     Abstract available


  159. STIEB S, Mohamed ASR, He R, Zhu LL, et al
    Development and validation of a contouring guideline for the taste bud bearing tongue mucosa.
    Radiother Oncol. 2021;157:63-69.
    PubMed     Abstract available


    March 2021
  160. PATEL S, Patel N, Sassoon I, Patel V, et al
    The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws.
    Radiother Oncol. 2021;156:209-216.
    PubMed     Abstract available


  161. AKBABA S, Ruhle A, Rothhaar S, Zamboglou C, et al
    Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - Results from a large multicenter analysis.
    Radiother Oncol. 2021;156:266-274.
    PubMed     Abstract available


  162. THOMAS M, Mortensen HR, Hoffmann L, Moller DS, et al
    Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer.
    Radiother Oncol. 2021;156:102-112.
    PubMed     Abstract available


  163. HOSNI A, Huang SH, Xu W, Su J, et al
    Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma.
    Radiother Oncol. 2021;156:95-101.
    PubMed     Abstract available


    February 2021
  164. DIETRICH A, Andreeff M, Koi L, Bergmann R, et al
    Radiotherapy enhances uptake and efficacy of (90)Y-cetuximab: A preclinical trial.
    Radiother Oncol. 2021;155:285-292.
    PubMed     Abstract available


  165. MICHAELIDOU A, Adjogatse D, Suh Y, Pike L, et al
    18F-FDG-PET in guided dose-painting with intensity modulated radiotherapy in oropharyngeal tumours: A phase I study (FiGaRO).
    Radiother Oncol. 2021;155:261-268.
    PubMed     Abstract available


  166. ROSEN BS, Wilkie JR, Sun Y, Ibrahim M, et al
    CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Radiother Oncol. 2021;155:174-181.
    PubMed     Abstract available


    January 2021
  167. HOSNI A, Chiu K, Huang SH, Xu W, et al
    Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach.
    Radiother Oncol. 2021;154:70-75.
    PubMed     Abstract available


  168. NARAYAN RK, Kumari C, Panchal P, Ghosh SK, et al
    A macroscopic salivary gland and a potential organ or simply tubarial sero-mucinous glands?
    Radiother Oncol. 2021;154:324-325.
    PubMed    


  169. YAN D, Chen S, Krauss DJ, Deraniyagala R, et al
    Inter/intra-tumoral dose response variations assessed using FDG-PET/CT feedback images: Impact on tumor control and treatment dose prescription.
    Radiother Oncol. 2021;154:235-242.
    PubMed     Abstract available


  170. VALSTAR MH, de Bakker BS, Steenbakkers RJHM, de Jong KH, et al
    The tubarial salivary glands: A potential new organ at risk for radiotherapy.
    Radiother Oncol. 2021;154:292-298.
    PubMed     Abstract available


  171. WAGENAAR D, Kierkels RGJ, van der Schaaf A, Meijers A, et al
    Head and neck IMPT probabilistic dose accumulation: Feasibility of a 2 mm setup uncertainty setting.
    Radiother Oncol. 2021;154:45-52.
    PubMed     Abstract available


  172. QIU X, Xu T, Li M, Fei Z, et al
    Response to Chai' letter: What caused the difference in prognosis among different physicians?
    Radiother Oncol. 2021;154:e20-e21.
    PubMed    


    December 2020
  173. VAN DER VEEN J, Willems S, Bollen H, Maes F, et al
    Deep learning for elective neck delineation: More consistent and time efficient.
    Radiother Oncol. 2020;153:180-188.
    PubMed     Abstract available


    October 2020
  174. LIU WC, Liu HE, Kao YW, Qin L, et al
    Definitive radiotherapy or surgery for early oral squamous cell carcinoma in old and very old patients: A propensity-score-matched, nationwide, population-based cohort study.
    Radiother Oncol. 2020;151:214-221.
    PubMed     Abstract available


  175. HAMILTON SN, Urban R, Liu A, Chau N, et al
    Population-based outcomes by immunosuppressed status in patients undergoing radiotherapy for oropharyngeal cancer.
    Radiother Oncol. 2020;151:110-117.
    PubMed     Abstract available


  176. LAI TY, Yeh CM, Hu YW, Liu CJ, et al
    Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy.
    Radiother Oncol. 2020;151:190-199.
    PubMed     Abstract available


  177. LERCH S, Berthold S, Ziemann F, Dreffke K, et al
    HPV-positive HNSCC cell lines show strongly enhanced radiosensitivity after photon but not after carbon ion irradiation.
    Radiother Oncol. 2020;151:134-140.
    PubMed     Abstract available


  178. SHARMA MB, Jensen K, Urbak SF, Funding M, et al
    A multidimensional cohort study of late toxicity after intensity modulated radiotherapy for sinonasal cancer.
    Radiother Oncol. 2020;151:58-65.
    PubMed     Abstract available


  179. ENGESETH GM, Stieb S, Mohamed ASR, He R, et al
    Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers.
    Radiother Oncol. 2020;151:119-125.
    PubMed     Abstract available


  180. ANAKOTTA RM, van der Laan HP, Visser S, Ribeiro CO, et al
    Weekly robustness evaluation of intensity-modulated proton therapy for oesophageal cancer.
    Radiother Oncol. 2020;151:66-72.
    PubMed     Abstract available


    August 2020
  181. BEUKEMA JC, Kawaguchi Y, Sijtsema NM, Zhai TT, et al
    Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?
    Radiother Oncol. 2020;149:222-227.
    PubMed     Abstract available


  182. GOTTGENS EL, Bussink J, Ansems M, Hammond EM, et al
    AKT inhibition as a strategy for targeting hypoxic HPV-positive HNSCC.
    Radiother Oncol. 2020;149:1-7.
    PubMed     Abstract available


    July 2020
  183. JOURNY N, Schonfeld SJ, Hauptmann M, Roberti S, et al
    Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer.
    Radiother Oncol. 2020 Jul 14. pii: S0167-8140(20)30415.
    PubMed     Abstract available


  184. WENTZEL A, Hanula P, van Dijk LV, Elgohari B, et al
    Precision toxicity correlates of tumor spatial proximity to organs at risk in cancer patients receiving intensity-modulated radiotherapy.
    Radiother Oncol. 2020;148:245-251.
    PubMed     Abstract available


  185. VAN DEN BOSCH L, Schuit E, van der Laan HP, Reitsma JB, et al
    Key challenges in normal tissue complication probability model development and validation: towards a comprehensive strategy.
    Radiother Oncol. 2020;148:151-156.
    PubMed     Abstract available


  186. KAANDERS JHAM, van den Bosch S, Dijkema T, Al-Mamgani A, et al
    Advances in cancer imaging require renewed radiotherapy dose and target volume concepts.
    Radiother Oncol. 2020;148:140-142.
    PubMed     Abstract available


  187. GRANT SR, Hutcheson KA, Ye R, Garden AS, et al
    Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer.
    Radiother Oncol. 2020;148:133-139.
    PubMed     Abstract available


  188. SAKSO M, Jensen K, Andersen M, Hansen CR, et al
    DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx,
    Radiother Oncol. 2020;148:65-72.
    PubMed     Abstract available


  189. WILKIE JR, Mierzwa ML, Casper KA, Mayo CS, et al
    Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics.
    Radiother Oncol. 2020;148:30-37.
    PubMed     Abstract available


    June 2020
  190. VAN DER HEIJDEN M, Essers PBM, Verhagen CVM, Willems SM, et al
    Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy.
    Radiother Oncol. 2020;147:186-194.
    PubMed     Abstract available


  191. MANZAR GS, Lester SC, Routman DM, Harmsen WS, et al
    Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.
    Radiother Oncol. 2020;147:64-74.
    PubMed     Abstract available


  192. HANSEN CR, Bertelsen A, Zukauskaite R, Johnsen L, et al
    Prediction of radiation-induced mucositis of H&N cancer patients based on a large patient cohort.
    Radiother Oncol. 2020;147:15-21.
    PubMed     Abstract available


    April 2020
  193. VISCHIONI B, Dhanireddy B, Severo C, Bonora M, et al
    Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO.
    Radiother Oncol. 2020;145:172-177.
    PubMed     Abstract available


  194. DE FELICE F, Bird T, Michaelidou A, Thavaraj S, et al
    Radical (chemo)radiotherapy in oropharyngeal squamous cell carcinoma: Comparison of TNM 7th and 8th staging systems.
    Radiother Oncol. 2020;145:146-153.
    PubMed     Abstract available


  195. NG SP, Bahig H, Jethanandani A, Pollard C, et al
    Lymphopenia during radiotherapy in patients with oropharyngeal cancer.
    Radiother Oncol. 2020;145:95-100.
    PubMed     Abstract available


    March 2020
  196. WONG J, Fong A, McVicar N, Smith S, et al
    Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning.
    Radiother Oncol. 2020;144:152-158.
    PubMed     Abstract available


  197. HUANG SH, O'Sullivan B, Su J, Bartlett E, et al
    Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification.
    Radiother Oncol. 2020;144:13-22.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: